Abstract

Liver transplantation is the only recognized effective treatment for end-stage liver disease. However, organ shortages have become the main challenge for patients and physicians within the transplant community. Waiting list mortality remains an issue with around 10% of patients dying whilst waiting for an available organ. The post-transplantation period is also associated with an adverse complication rate for these specific cohorts of high-risk patients, particularly regarding patient and graft survival. Ischaemia reperfusion injury (IRI) has been highlighted as the mechanism of injury that increases parenchymal damage, which eventually lead to significant graft dysfunction and other poor outcome indicators. The consequences of IRI in clinical practice such as reperfusion syndrome, primary non-function of graft, allograft dysfunction, ischaemic biliary damage and early biliary complications can be life-threatening. IRI dictates the development of a significant inflammatory response that drives the pathway to eventual cell death. The main mechanisms of IRI are mitochondrial damage due to low oxygen tension within the hepatic micro-environment and severe adenosine triphosphate (ATP) depletion during the ischaemic period. After the restoration of normal blood flow, this damage is further enhanced by reoxygenation as the mitochondria respond to reperfusion by releasing reactive oxygen species (ROS), which in turn activate Kupffer cells within the hepatic micro-environment, leading to a pro-inflammatory response and eventual parenchymal cell apoptosis and associated tissue degradation. Machine perfusion (MP) is one emergent strategy considered to be one of the most important advances in organ preservation, restoration and transplantation. Indeed, MP has the potential to rescue frequently discarded organs and has been shown to limit the extent of IRI, leading to suppression of the deleterious pro-inflammatory response. This immunomodulation reduces the prevalence of allograft rejection, the use of immunosuppression therapy and minimizes post-transplant complications. This review aims to update the current knowledge of MP with a focus on normothermic machine liver perfusion (NMLP) and its potential role in immune response pathways.

Highlights

  • Liver transplantation (LT) is the only effective and definitive therapy for end stage liver disease

  • Extended Criteria Donors (ECD) are considered to be: [1] older aged (≥60 years old) brain death donors (DBD), [2] donors with underlying medical co-morbidities(two of either stroke, hypertension, or serum creatinine >1.5 mg/dL), [3] donors with high-grade steatosis, and [4] cardiac death donors (DCD) or donors whose liver is subjected to prolonged cold ischaemia time (CIT)

  • damage associated molecular patterns (DAMPs) generated are recognized by pathogen recognition receptors (PRRs), such as Toll-like receptors (TLRs) and cytoplasmic Nod-like receptors (NLRs), which drive an immune response

Read more

Summary

Organ Restoration With Normothermic Machine Perfusion and Immune Reaction

Alessandro Parente 1†, Daniel-Clement Osei-Bordom , 1,2,3† Vincenzo Ronca , 1,2,4 M. After the restoration of normal blood flow, this damage is further enhanced by reoxygenation as the mitochondria respond to reperfusion by releasing reactive oxygen species (ROS), which in turn activate Kupffer cells within the hepatic micro-environment, leading to a pro-inflammatory response and eventual parenchymal cell apoptosis and associated tissue degradation. MP has the potential to rescue frequently discarded organs and has been shown to limit the extent of IRI, leading to suppression of the deleterious pro-inflammatory response. This immunomodulation reduces the prevalence of allograft rejection, the use of immunosuppression therapy and minimizes post-transplant complications.

INTRODUCTION
THE RATIONALE OF ORGAN PRESERVATION BY MACHINE PERFUSION
NORMOTHERMIC MACHINE PERFUSION
NORMOTHERMIC MACHINE PERFUSION FOR ORGAN PRESERVATION
Donor type
IMMUNE RESPONSE AND NMLP
THE FUTURE OF ORGAN PRESERVATION
Findings
AUTHOR CONTRIBUTIONS

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.